Immunonutrition in Ulcerative Colitis

Clinical Trial ID: NCT03594708

This study tests the hypothesis that a supplement that combines a functional fiber, long chain omega-3 polyunsaturated fatty acids (PUFAs), vitamin D3, vitamin E, and zinc will reduce clinical symptoms, decrease pro-inflammatory cytokines in the blood and ergo decrease inflammation, promote beneficial microbial activity in the colon, and help recovery of the intestinal mucosa of ulcerative colitis (UC) patients compared with a placebo.

An anticipated 30 participants with newly diagnosed active ulcerative colitis will be recruited to participate in a randomized control trial, with 50% of the subjects distributed to the supplement (n=15) and the other 50% provided a placebo control (n=15). This is considered as a "proof of concept" study to determine if there is evidence that a multi-ingredient supplement (immunonutrition) will reduce UC disease severity.

Inclusion Criteria: - patients with active ulcerative colitis (proof of diagnosis from gastroenterologist), over 18 years old, has over 50% gut remaining, fully connected bowels (no colostomy), currently on 5-aminosalicylates (ASA) drugs, not pregnant or lactating Exclusion Criteria: -

Start Date
2018-04-30
Last Updated
2018-07-11
Sponsor
Baptist Memorial Health Care Corporation
Condition Name
Ulcerative Colitis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Visit clinicaltrials.gov

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.

Clinicaltrials.gov

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and...

This is an open-label, prospective, observational study with the primary objective to characterize the pharmacokinetics of infliximab in patients with Acute Severe Ulcerative Colitis.

Trial Type

Observational

Sponsorship

Robarts Clinical Trials Inc.

Clinicaltrials.gov

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active...

Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Allergan

Clinicaltrials.gov

Safety and Efficacy Trial of RPC1063 for Moderate to Severe...

The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).

Trial Type

Interventional

Trial Phase

Phase 3

Sponsorship

Celgene

Clinicaltrials.gov

An Observational Prospective Long-term Exposure Registry of Adult...

The purpose of this study is to compare the incidence of lymphoma in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi versus those treated with thiopurines.

Trial Type

Observational

Sponsorship

Janssen Biotech, Inc.

Clinicaltrials.gov

Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe...

To evaluate the efficacy and safety of Neihulizumab (AbGn-168H) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

AbGenomics International, Inc.

Clinicaltrials.gov

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC)...

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Takeda

Clinicaltrials.gov

Low Dose IL-2 for Ulcerative Colitis

The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Scott Snapper

Clinicaltrials.gov

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy in moderate-to-severe...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Immunic AG

Clinicaltrials.gov

TUDCA as a Therapy for Ulcerative Colitis (UC)

This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Crohn's and Colitis Foundation

Clinicaltrials.gov

The Role of Secondary Bile Acids in Intestinal Inflammation

The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in the production of molecules that impact health-are widely accepted to play a key role. A significant proportion of...

Trial Type

Interventional

Trial Phase

Phase 2/Phase 3

Sponsorship

Stanford University

Clinicaltrials.gov

Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)

Ulcerative colitis (UC) is a chronic, progressive immunologically mediated disease affecting nearly 1 million Americans. Up to one third of patients with UC will require hospitalization for severe disease...

Trial Type

Observational

Sponsorship

Icahn School of Medicine at Mount Sinai

Clinicaltrials.gov

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to...

The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Pfizer

Clinicaltrials.gov

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate...

The goal of the study is to evaluate strategies that target the microbiota for the treatment of Ulcerative Colitis , This study will involve a novel diet that the investigators developed , based on the...

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

Prof. Arie Levine

Clinicaltrials.gov

The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in...

Ninety Six patients with mild to moderate ulcerative colitis will be randomized to double blind, placebo controlled study. The safety and efficacy of the intervention will be closely monitored.

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Children's Hospital Los Angeles

Clinicaltrials.gov

Efficacy & Safety of TD-1473 in Ulcerative Colitis

A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of...

Trial Type

Interventional

Trial Phase

Phase 2/Phase 3

Sponsorship

Theravance Biopharma

Clinicaltrials.gov

Low Sulfur Fecal Transplant for Ulcerative Colitis

The purpose of this study is to evaluate the engraftment of donor microbiota's sulfate reducing bacteria (SRB) in subjects with active ulcerative colitis (UC) following sequential fecal microbiota transplant...

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

University of Minnesota

Clinicaltrials.gov

Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease...

Although Crohn's disease and ulcerative colitis are the main subtypes of inflammatory bowel disease, they differ substantially in disease behavior, prognosis, and treatment paradigm. However, making an...

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

Carilion Clinic

Clinicaltrials.gov

Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative...

This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 induction compared to...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Landos Biopharma Inc.

Clinicaltrials.gov

Reactive vs. Proactive Pain Control in IBD

The investigators will compare two physician behaviors for managing pain in patients with IBD: proactive vs. reactive. Both the proactive and reactive behavior/strategies are standard of care at the...

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

Cedars-Sinai Medical Center

Clinicaltrials.gov

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and...

The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease. Two cohorts of patients will be enrolled, based on...

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Bristol-Myers Squibb

Clinicaltrials.gov

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate...

This is a prospective unblinded, randomized trial for the use of Fecal Microbiota Transplantation (FMT) for the treatment of Ulcerative Colitis (UC), in combination with or without antibiotic pretreatment.

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Najwa Elnachef

Clinicaltrials.gov

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe...

The purpose of this study is to determine the long-term safety of RPC1063 for the treatment of all patients with moderate to severe Ulcerative Colitis (UC) as well as the long-term efficacy of RPC1063 for the...

Trial Type

Interventional

Trial Phase

Phase 3

Sponsorship

Celgene

Clinicaltrials.gov

A Study to Assess Efficacy and Safety of SER‑287 in Adults With...

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Seres Therapeutics, Inc.

Clinicaltrials.gov

A Study of Guselkumab in Participants With Moderately to Severely...

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

Trial Type

Interventional

Trial Phase

Phase 2/Phase 3

Sponsorship

Janssen Research & Development, LLC

Immunonutrition in Ulcerative Colitis

Description

Criteria

Start Date

Last Updated

Sponsor

Condition Name

Learn about this trial.

Related Trials

Clinicaltrials.gov

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and...

Clinicaltrials.gov

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active...

Clinicaltrials.gov

Safety and Efficacy Trial of RPC1063 for Moderate to Severe...

Clinicaltrials.gov

An Observational Prospective Long-term Exposure Registry of Adult...

Clinicaltrials.gov

Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe...

Clinicaltrials.gov

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC)...

Clinicaltrials.gov

Low Dose IL-2 for Ulcerative Colitis

Clinicaltrials.gov

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Clinicaltrials.gov

TUDCA as a Therapy for Ulcerative Colitis (UC)

Clinicaltrials.gov

The Role of Secondary Bile Acids in Intestinal Inflammation

Clinicaltrials.gov

Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)

Clinicaltrials.gov

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to...

Clinicaltrials.gov

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate...

Clinicaltrials.gov

The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in...

Clinicaltrials.gov

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Clinicaltrials.gov

Low Sulfur Fecal Transplant for Ulcerative Colitis

Clinicaltrials.gov

Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease...

Clinicaltrials.gov

Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative...

Clinicaltrials.gov

Reactive vs. Proactive Pain Control in IBD

Clinicaltrials.gov

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and...

Clinicaltrials.gov

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate...

Clinicaltrials.gov

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe...

Clinicaltrials.gov

A Study to Assess Efficacy and Safety of SER‑287 in Adults With...

Clinicaltrials.gov

A Study of Guselkumab in Participants With Moderately to Severely...